Skip to search formSkip to main contentSkip to account menu

solifenacin succinate 5 MG Oral Tablet [Vesicare]

Known as: SOLIFENACIN SUCCINATE 5 mg ORAL TABLET, FILM COATED [VESIcare], VESIcare 5 MG Oral Tablet 
National Institutes of Health

Related topics

Related topics

4 relations
Oral TabletSolifenacinVesicaresolifenacin succinate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
The effect of solifenacin on postvoid dribbling in women: results of a randomized, double-blind placebo-controlled trial
Introduction and hypothesisTo determine the effectiveness of the muscarinic receptor antagonist solifenacin (VESIcare®) in the… 
2014
2014
URGE-PD: A Multi-Site, Double-Blind, Randomized, Placebo-Controlled Trial of Solifenacin succinate (VESIcare®) for the Treatment of Overactive Bladder in Parkinson’s Disease
2014
2014
An Open Label Study of Solifenacin Succinate (VESIcare®) for the Treatment of Overactive Bladder in Parkinson’s Disease
2006
2006
Solifenacin (Vesicare®)—治療膀胱過動症再添新藥
2006
2006
URGE-PD: A Multi-Site, Double-Blind, Randomized, Placebo Controlled Trial of Solifenacin Succinate (VESIcare®) for the Treatment of Urinary Dysfunction in Parkinson's Disease
Review
2005
Review
2005
Novel muscarinic antagonists to treat incontinence and/or overactive bladder ☆
2004
2004
Solifenacin Demonstrates High Absolute Bioavailability in Healthy Men
ObjectiveSolifenacin succinate (YM905; Vesicare®) is a promising new bladder selective muscarinic receptor antagonist under… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)